Chief Executive Officer
Philippe Rousseau has over 25 years of experience in the biotech industry in Europe and the US in C-Level positions. Prior to joining Xenothera, Philippe was Chief Financial Officer of Biophytis SA, a dual listed late-stage clinical biotech company and Chief Operating Officer of Pherecydes Pharma, an antibacterial clinical stage company that he listed on Euronext Growth in 2021. He had also been deputy CEO of the Swiss biomarker and diagnostics company ABCDx, CEO of CYTOO Inc. in the US, and acting CEO of ExonHit Therapeutics that he IPOed in 2005. Before joining the biotechnology industry 25 years ago when he was recruited by Genset, Philippe started his career in investment banking and strategic consulting. Philippe Rousseau has an extensive expertise in management of biotechnology companies, in financial transactions, strategic planning and development of life science companies on both sides of the Atlantic.